A RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, SAFETY AND EXPLORATORY EFFICACY AND PHARMACOKINETIC, STUDY OF RO4917523 IN PEDIATRIC PATIENTS WITH FRAGILE X SYNDROME
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2016
Price : $35 *
At a glance
- Drugs Basimglurant (Primary)
- Indications Fragile X syndrome
- Focus Adverse reactions
- Sponsors Roche
- 26 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by Clinical Trial.Gov record.
- 23 Jul 2013 Planned end date changed from 1 Oct 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.